|
| Press Releases |
|
 |
|
| Wednesday, March 23, 2022 |
|
|
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities |
| Singapore Exchange-listed Alset International Ltd (SGX Stock Code: 40V) ("Alset", the "Company" or together with its subsidiaries, the "Group) wishes to announce that the Company has plans to embark on cryptocurrency mining business through its subsidiary Alset Mining Pte. Ltd. ("Alset Mining"). more info >> |
|
| Monday, February 21, 2022 |
|
|
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option |
| Alset Capital Acquisition Corp. (the "Company") announced on February 3, 2022 the closing of its initial public offering of 7,500,000 units at $10.00 per unit (the "Offering"). more info >> |
|
| Monday, October 5, 2020 |
|
|
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc. |
| Document Security Systems, Inc. today announced its wholly owned subsidiary Impact BioMedical, Inc. ("Impact BioMedical") has formed a new wholly owned subsidiary, Innate Immune, Inc. ("Innate Immune"), to initiate efficacy testing of a pancoronavirus vaccine, a special type of vaccine designed to protect against multiple coronaviruses. more info >> |
|
| Friday, September 18, 2020 |
|
|
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance |
| Document Security Systems, Inc. (NYSE American: DSS) today announced its wholly owned subsidiary Impact BioMedical, Inc., through its subsidiary Global BioLife, Inc., completed efficacy testing of its proprietary 3F Antiviral Biofragrance at a biosafety level 3 containment facility at an independent university. more info >> |
|
| Friday, July 31, 2020 |
|
|
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. ("Impact"), announced today the initiation of Quantum, their research program designed to solve the impending pharmaceutical patent cliff threat. more info >> |
|
| Wednesday, June 24, 2020 |
|
|
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that they proved in vitro success of Equivir and 3F Biofragrance against COVID-19 in independent laboratory testing. more info >> |
|
| Wednesday, June 17, 2020 |
|
|
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that their COVID-19 research with Global Research and Discovery Group Sciences ("GRDG"), conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. ("Vilotos"), was published in the peer-reviewed scientific journal Molecules on June 11, 2020. more info >> |
|
| Monday, June 1, 2020 |
|
|
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc., would like to update its stakeholders on its suite of antiviral and medical technologies. more info >> |
|
| Friday, April 24, 2020 |
|
|
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts |
| SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced recently that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). more info >> |
|
| Wednesday, March 18, 2020 |
|
|
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak |
| Singapore Exchange-listed Singapore eDevelopment Limited has announced that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. ("GRDG"), recently conducted molecular docking studies, utilizing advanced computational models, which indicate Linebacker and Equivir successfully inhibit infection of SARS-CoV-2, the virus responsible for the COVID-19 outbreak. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
天能动力公布2022年全年业绩
Mar 25, 2023 09:57 HKT/SGT
|
|
|
天能動力公佈2022年全年業績
Mar 25, 2023 09:56 HKT/SGT
|
|
|
Tianneng Power Announces 2022 Annual Results
Mar 25, 2023 09:55 HKT/SGT
|
|
|
天韵国际公布2022年全年业绩
Mar 24, 2023 23:24 HKT/SGT
|
|
|
天韵國際公佈2022年全年業績
Mar 24, 2023 23:23 HKT/SGT
|
|
|
Tianyun International Announced 2022 Annual Results
Mar 24, 2023 23:22 HKT/SGT
|
|
|
安乐工程2022全年收益及获授合约逆市增加21.0%及41.8%
Mar 24, 2023 22:11 HKT/SGT
|
|
|
安樂工程2022全年收益及獲授合約逆市增加21.0%及41.8%
Mar 24, 2023 22:10 HKT/SGT
|
|
|
Analogue Grows FY2022 Revenue and Contracts Awarded by 21.0% and 41.8% Respectively Defying Challenging Market Conditions
Mar 24, 2023 22:09 HKT/SGT
|
|
|
四环医药（0460.HK）发布2022年全年业绩
Mar 24, 2023 19:18 HKT/SGT
|
|
|
四環醫藥（0460.HK）發佈2022年全年業績
Mar 24, 2023 19:17 HKT/SGT
|
|
|
Sihuan Pharmaceutical (0460.HK) Announces 2022 Annual Results
Mar 24, 2023 19:16 HKT/SGT
|
|
|
DepEd leaders, local school leaders and EdTech experts gather to discuss the future of K-12 education and hybrid learning in Manila this April
Mar 24, 2023 18:00: JST
|
|
|
富士通など、量子コンピュータを利用できる「量子計算クラウドサービス」開始
Mar 24, 2023 18:00: JST
|
|
|
祖龙娱乐发布2022年度业绩
Mar 24, 2023 17:55 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
